Skip to Main content Skip to Navigation
Journal articles

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice

Abstract : Obesity and/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production. Mineralocorticoid receptor antagonists have proven their clinical efficacy in diabetic kidney disease with preclinical data suggesting that they may also be efficient in non-diabetic chronic kidney disease associated to metabolic diseases. In the present study we developed a novel mouse model combining severe nephron reduction and High Fat Diet challenge that led to chronic kidney disease with metabolic alterations. We showed that the Mineralocorticoid Receptor antagonist canrenoate improved metabolic function, reduced albuminuria and prevented the synergistic effect of high fat diet on renal fibrosis and inflammation in chronic kidney disease mice.
Complete list of metadata

https://hal-univ-paris.archives-ouvertes.fr/hal-03694010
Contributor : Equipe HAL Université Paris Cité Connect in order to contact the contributor
Submitted on : Monday, June 13, 2022 - 12:06:10 PM
Last modification on : Saturday, June 25, 2022 - 3:44:21 AM

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Links full text

Identifiers

Citation

Roberto Palacios-Ramirez, Ixchel Lima-Posada, Benjamin Bonnard, Marie Genty, Amaya Fernandez-Celis, et al.. Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice. Frontiers in Physiology, Frontiers, 2022, 13, ⟨10.3389/fphys.2022.859812⟩. ⟨hal-03694010⟩

Share

Metrics

Record views

0